Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rege Nephro Co. Ltd. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, ensuring separate reviews for each matter. Both of these pending actions are located within 1 distinct art unit, suggesting a concentration of the company's biotechnology intellectual property. This arrangement indicates a focused technical scope for the company's current intellectual property filings.
The busiest examiner for the portfolio is MATALKAH, FATIMAH KHALAF, who is currently handling 1 pending office action. With a total of 2 pending office actions, the workload is divided between the 2 distinct examiners. The presence of 2 distinct examiners within 1 distinct art unit for these 2 actions indicates a focused but diversified examination process. For a practitioner, this means coordinating with 2 different examiners who are likely working in the same specialized group, which requires a consistent approach to technical arguments across both pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| O'NEILL, MARISOL ANN | 1 | 53.1% | +68.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 21d |
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 21d |
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | — | §103§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 1633 | §102§103§112 | Final Rejection | 21d | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial